EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology

Lisa C Heather iD, Keshav Gopal, Nikola Srnic, John R Ussher iD

Diabetes · 01.05.2024 · 73 (5) · 659-670

DOI: 10.2337/dbi23-0019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 22.02.2024. Verfasst von Lisa C Heather und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, U.K. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Heart Failure, Hypertension, Diabetes Mellitus. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation, CIHR, Diabetes Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease represents the leading cause of death in people with diabetes, most notably from macrovascular diseases such as myocardial infarction or heart failure. Diabetes also increases the risk of a specific form of cardiomyopathy, referred to as diabetic cardiomyopathy (DbCM), originally defined as ventricular dysfunction in the absence of underlying coronary artery disease and/or hypertension. Herein, we provide an overview on the key mediators of DbCM, with an emphasis on the role for perturbations in cardiac substrate metabolism. We discuss key mechanisms regulating metabolic dysfunction in DbCM, with additional focus on the role of metabolites as signaling molecules within the diabetic heart. Furthermore, we discuss the preclinical approaches to target these perturbations to alleviate DbCM. With several advancements in our understanding, we propose the following as a new definition for, or approach to classify, DbCM: “diastolic dysfunction in the presence of altered myocardial metabolism in a person with diabetes but absence of other known causes of cardiomyopathy and/or hypertension.” However, we recognize that no definition can fully explain the complexity of why some individuals with DbCM exhibit diastolic dysfunction, whereas others develop systolic dysfunction. Due to DbCM sharing pathological features with heart failure with preserved ejection fraction (HFpEF), the latter of which is more prevalent in the population with diabetes, it is imperative to determine whether effective management of DbCM decreases HFpEF prevalence. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesHeart FailureHypertensionDiabetes MellitusHumansStroke Volume

Autor:innen und Institutionen

  • Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, U.K.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada.

ORCID-Profile: Lisa C Heather, John R Ussher

Förderung

  • British Heart Foundation
  • CIHR
  • Diabetes Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Heather, L. C., Gopal, K., Srnic, N., & Ussher, J. R. (2024). Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology. Diabetes, 73(5), 659-670. https://doi.org/10.2337/dbi23-0019

Vancouver

Heather LC, Gopal K, Srnic N, Ussher JR. Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology. Diabetes. 2024;73(5):659-670. doi:10.2337/dbi23-0019

BibTeX
@article{Heather2024,
  author = {Heather, Lisa C and Gopal, Keshav and Srnic, Nikola and Ussher, John R},
  title = {Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology},
  journal = {Diabetes},
  year = {2024},
  volume = {73},
  number = {5},
  pages = {659--670},
  doi = {10.2337/dbi23-0019}
}
Kostenlos starten →